Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Henry Schein is a medical distribution business based in the US. Henry Schein shares (HSIC) are listed on the NASDAQ and all prices are listed in US Dollars. Henry Schein employs 22,000 staff and has a trailing 12-month revenue of around $12.6 billion.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $86.74 |
|---|---|
| 52-week range | $64.75 - $92.68 |
| 50-day moving average | $82.05 |
| 200-day moving average | $77.67 |
| Wall St. target price | $83.45 |
| PE ratio | 19.0678 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $4.57 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $86.74 from 2023-02-08
| 1 week (2023-02-02) | -2.63% |
|---|---|
| 1 month (2023-01-09) | 7.71% |
| 3 months (2022-11-09) | 16.54% |
| 6 months (2022-08-09) | 15.01% |
| 1 year (2022-02-09) | 13.28% |
|---|---|
| 2 years (2021-02-09) | 22.84% |
| 3 years (2020-02-07) | 23.97% |
| 5 years (2018-02-09) | 54.22% |
Valuing Henry Schein stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Henry Schein's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Henry Schein's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Henry Schein shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Henry Schein's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9368. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Henry Schein's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Henry Schein's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Henry Schein's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $12.6 billion |
|---|---|
| Operating margin TTM | 6.97% |
| Gross profit TTM | $3.7 billion |
| Return on assets TTM | 6.48% |
| Return on equity TTM | 14.01% |
| Profit margin | 5.06% |
| Book value | $26.70 |
| Market capitalisation | $11.8 billion |
TTM: trailing 12 months
We're not expecting Henry Schein to pay a dividend over the next 12 months.
Henry Schein's shares were split on a 1275:1000 basis on 7 February 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1275 shares. This wouldn't directly have changed the overall worth of your Henry Schein shares – just the quantity. However, indirectly, the new 21.6% lower share price could have impacted the market appetite for Henry Schein shares which in turn could have impacted Henry Schein's share price.
Over the last 12 months, Henry Schein's shares have ranged in value from as little as $64.75 up to $92.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Henry Schein's is 0.7887. This would suggest that Henry Schein's shares are less volatile than average (for this exchange).
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.